Hosted on MSN8mon
FDA Clears NeuroStar TMS Therapy for Adolescents with Depression, A First in the FieldMALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has announced that the U.S. Food and Drug Administration (FDA) has cleared NeuroStar TMS (transcranial magnetic stimulation) for use as a first ...
MyChesCo on MSN3mon
Neuronetics Enhances NeuroStar Therapy with New FeaturesMALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has announced significant enhancements to its NeuroStar Advanced Therapy and ...
Total Revenue: $18.5 million, a 4% increase over the third quarter of 2023. NeuroStar System Revenue: $4.1 million with 49 systems shipped. US Treatment Session Revenue: $13.3 million, a 2% increase ...
Total Revenue: $18.5 million, a 4% increase over the third quarter of 2023. NeuroStar System Revenue: $4.1 million with 49 systems shipped. US Treatment Session Revenue: $13.3 million, a 2% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results